Laura J. Esserman, MD, MBA

Harvard University, A.B., 1977, History of Science
Stanford University, M.D., 1983, Surgery
Stanford University, School of Business, M.B.A., 1993, Health Policy

• 1985-1988
  Postdoctoral Fellow, Dept. of Medicine, Division of Oncology, Stanford University School of Medicine
• 1988-1990/1983-1985
  Resident in General Surgery, Stanford University School of Medicine
• 1990-1991
  Chief Resident in General Surgery, Stanford University School of Medicine
• 1991-1993
  Consultant, Stanford University Hospital, Cost Benefit Issues in the ICU
• 1992-1993
  Staff General Surgeon, Palo Alto VeteranOs Administration
• 1991-1993
  Trauma Surgeon, Santa Clara Valley Medical Center
• 06/92-8/93
  Clinical Assistant Professor of Surgery, Stanford University Department of Surgery
• 09/93-present
  Co-Director, Carol Franc Buck Breast Care Center, UCSF/Mount Zion Cancer Center, San Francisco, CA
• 09/93-5/04
  Assistant Professor of Surgery, UCSF/Mount Zion Medical Center
• 06/96-present
  Affiliate Faculty, Institute for Health Policy Studies, University of California, San Francisco, CA
• 07/96-present
  Co-Director, High-Risk Program for Breast and Ovarian Cancer, UCSF/Mount Zion Cancer Center, San Francisco, CA
• 04/97-present
  Joint Appointment, Department of Radiology, University of California, San Francisco, CA
• 06/97-present
  Executive Committee, Integrative Medicine Program, UCSF/Mount Zion Cancer Center, San Francisco, CA, Associate Professor, Surgery & Radiology
• 07/97-present
  Director, UCSF Carol Franc Buck Breast Care Center, UCSF Helen Diller Family Comprehensive Cancer Center at Mt. Zion, San Francisco, CA
• 06/98-present
  Clinical Program Leader, Breast Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center at Mt. Zion, San Francisco, CA
• 6/04-present
  Professor of Surgery and Radiology, UCSF/Mount Zion Medical Center
• 2008-present
  Associate Director (Translational Informatics), Helen Diller Family Comprehensive Cancer Center, UCSF/Mount Zion Cancer Center, San Francisco, CA

• 1974 Harvard University-Sophomore Standing
• 1974, 75, 77 John J. Fomon Research Fellowship (American Cancer Society)
• 1975 Harvard University-Susan B. Anthony Potter Prize
• 1977 Harvard University-Magna Cum Laude
• 1992 Certification: Board Certified, American College of Surgeons
• 1998-2008 Breast Cancer Research Foundation Award
• 2003 Showcase for Biotechnology
• 2003 Landmark Lecture Award Windber Research Institute
• 2005 SPORE (Specialized Programs of Research Excellence) Outstanding Investigator of the Year
• 2007 Best Poster – Breast Oncology Program
• 2008 Best Poster – Breast Oncology Program

• Esserman LJ, Woodcock J. Accelerating identification and regulatory approval of investigational cancer drugs. JAMA. 2011 Dec 21; 306(23):2608-9.
• Loi S, Symmans WF, Bartlett JM, Fumagalli D, Veer LV, Forbes JF, Bedard P, Denkert C, Zujewski J, Viale G, Pusztai L, Esserman LJ, Leyland-Jones BR. Proposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: timing and specimen types. Lancet Oncol. 2011 Nov; 12(12):1162-8.
• Esserman LJ, Shieh Y, Rutgers EJ, Knauer M, Retèl VP, Mook S, Glas AM, Moore DH, Linn S, van Leeuwen FE, van 't Veer LJ. Impact of mammographic screening on the detection of good and poor prognosis breast cancers. Breast Cancer Res Treat. 2011 Dec; 130(3):725-34.
• Meyerson AF, Lessing JN, Itakura K, Hylton NM, Wolverton DE, Joe BN, Esserman LJ, Hwang ES. Outcome of long term active surveillance for estrogen receptor-positive ductal carcinoma in situ. Breast. 2011 Dec; 20(6):529-33.
• Mukhtar RA, Moore AP, Nseyo O, Baehner FL, Au A, Moore DH, Twomey P, Campbell MJ, Esserman LJ. Elevated PCNA+ tumor-associated macrophages in breast cancer are associated with early recurrence and non-Caucasian ethnicity. Breast Cancer Res Treat. 2011 Nov; 130(2):635-44.
• Esserman LJ, Moore DH, Tsing PJ, Chu PW, Yau C, Ozanne E, Chung RE, Tandon VJ, Park JW, Baehner FL, Kreps S, Tutt AN, Gillett CE, Benz CC. Biologic markers determine both the risk and the timing of recurrence in breast cancer. Breast Cancer Res Treat. 2011 Sep; 129(2):607-16.
• Hatzis C, Pusztai L, Valero V, Booser DJ, Esserman L, Lluch A, Vidaurre T, Holmes F, Souchon E, Wang H, Martin M, Cotrina J, Gomez H, Hubbard R, Chacón JI, Ferrer-Lozano J, Dyer R, Buxton M, Gong Y, Wu Y, Ibrahim N, Andreopoulou E, Ueno NT, Hunt K, Yang W, Nazario A, DeMichele A, O'Shaughnessy J, Hortobagyi GN, Symmans WF. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA. 2011 May 11; 305(18):1873-81.
• Ellis MJ, Suman VJ, Hoog J, Lin L, Snider J, Prat A, Parker JS, Luo J, Deschryver K, Allred DC, Esserman LJ, Unzeitig GW, Margenthaler J, Babiera GV, Marcom PK, Guenther JM, Watson MA, Leitch M, Hunt K, Olson JA. Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor-Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype--ACOSOG Z1031. J Clin Oncol. 2011 Jun 10; 29(17):2342-9.
• Ozanne EM, Shieh Y, Barnes J, Bouzan C, Hwang ES, Esserman LJ. Characterizing the impact of 25 years of DCIS treatment. Breast Cancer Res Treat. 2011 Aug; 129(1):165-73.
• Itakura K, Lessing J, Sakata T, Heinzerling A, Vriens E, Wisner D, Alvarado M, Esserman L, Ewing C, Hylton N, Hwang ES. The impact of preoperative magnetic resonance imaging on surgical treatment and outcomes for ductal carcinoma in situ. Clin Breast Cancer. 2011 Mar 1; 11(1):33-8.
• Mukhtar RA, Nseyo O, Campbell MJ, Esserman LJ. Tumor-associated macrophages in breast cancer as potential biomarkers for new treatments and diagnostics. Expert Rev Mol Diagn. 2011 Jan; 11(1):91-100.
• Hogarth M, Hajopoulos K, Young M, Cowles N, Churin J, Hornthal B, Esserman L. The Communication and Care Plan: a novel approach to patient-centered clinical information systems. J Biomed Inform. 2010 Oct; 43(5 Suppl):S6-8.
• Braithwaite D, Satariano WA, Sternfeld B, Hiatt RA, Ganz PA, Kerlikowske K, Moore DH, Slattery ML, Tammemagi M, Castillo A, Melisko M, Esserman L, Weltzien EK, Caan BJ. Long-term prognostic role of functional limitations among women with breast cancer. J Natl Cancer Inst. 2010 Oct 6; 102(19):1468-77.
• Campbell MJ, Tonlaar NY, Garwood ER, Huo D, Moore DH, Khramtsov AI, Au A, Baehner F, Chen Y, Malaka DO, Lin A, Adeyanju OO, Li S, Gong C, McGrath M, Olopade OI, Esserman LJ. Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome. Breast Cancer Res Treat. 2011 Aug; 128(3):703-11.
• Liu LC, Lang JE, Lu Y, Roe D, Hwang SE, Ewing CA, Esserman LJ, Morita E, Treseler P, Leong SP. Intraoperative frozen section analysis of sentinel lymph nodes in breast cancer patients: A meta-analysis and single-institution experience. Cancer. 2011 Jan 15; 117(2):250-8.
• Esserman L, Kaklamani V. Lessons learned from genetic testing. JAMA. 2010 Sep 1; 304(9):1011-2.
• Warren Peled A, Itakura K, Foster RD, Hamolsky D, Tanaka J, Ewing C, Alvarado M, Esserman LJ, Hwang ES. Impact of chemotherapy on postoperative complications after mastectomy and immediate breast reconstruction. Arch Surg. 2010 Sep; 145(9):880-5.
• Belkora JK, Teng A, Volz S, Loth MK, Esserman LJ. Expanding the reach of decision and communication aids in a breast care center: A quality improvement study. Patient Educ Couns. 2011 May; 83(2):234-9.
• Vaidya JS, Joseph DJ, Tobias JS, Bulsara M, Wenz F, Saunders C, Alvarado M, Flyger HL, Massarut S, Eiermann W, Keshtgar M, Dewar J, Kraus-Tiefenbacher U, Sütterlin M, Esserman L, Holtveg HM, Roncadin M, Pigorsch S, Metaxas M, Falzon M, Matthews A, Corica T, Williams NR, Baum M. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet. 2010 Jul 10; 376(9735):91-102.
• Chan LW, Rabban J, Hwang ES, Bevan A, Alvarado M, Ewing C, Esserman L, Fowble B. Is radiation indicated in patients with ductal carcinoma in situ and close or positive mastectomy margins? Int J Radiat Oncol Biol Phys. 2011 May 1; 80(1):25-30.